2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
1
Active Trials
200 recruiting
4
Rare Diseases
across 12 areas
0
News (30d)
Quiet
CStone Pharmaceuticals (Suzhou) Co., Ltd. is a company with 2 orphan drug designations across 4 rare diseases. Active clinical trials in 1 indication. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| hepatocellular carcinoma | Humanized Recombinant IgG4 Anti-PD-1 Monoclonal Antibody | Des.TrialAppr. |
| lymphoma | - | Des.TrialAppr. |
| malignant carotid body paraganglioma | Sugemalimab | Des.TrialAppr. |
| post-treatment Lyme disease syndrome | Sugemalimab | Des.TrialAppr. |
| treatment-refractory schizophrenia | Sugemalimab | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
87
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
87
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
1
affecting portfolio